Panagora Asset Management Inc Prothena Corp Public LTD CO Transaction History

Panagora Asset Management Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 10, 2021	SELL	$48.2 - $78.89 $160,168 - $262,151	-3,323 Closed	0 $0
Q2 2021 Aug 11, 2021	SELL	$21.63 - $57.65 $54,680 - $145,739	-2,528 Reduced 43.21%	3,323 $171,000
Q3 2020 Nov 13, 2020	SELL	$9.93 - $13.47 $844,784 - $1.15 Million	-85,074 Reduced 93.57%	5,851 $58,000
Q2 2020 Aug 12, 2020	BUY	$9.56 - $12.51 $116,765 - $152,797	12,214 Added 15.52%	90,925 $951,000
Q1 2020 May 14, 2020	BUY	$7.54 - $15.77 $593,480 - $1.24 Million	78,711 New	78,711 $842,000

198

44.5M

601K

259K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $604M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Panagora Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Panagora Asset Management Inc with notifications on news.